4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT completed enrollment for the 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD, with topline data expected in H2 2027, and reported positive 2-year data from the PRISM Phase 2b trial showing an up to 87% reduction in treatment burden. The company secured a $200 million strategic credit facility with Hercules Capital, drawing an initial $20 million, bringing the total cash position to $430.6 million to fund operations into the second half of 2028.
Key figures
- Revenue
- 3781000
- Guidance
- Cash runway expected to fund operations into second half of 2028
- Net loss
- 72936000
- Rd expenses
- 68282000
- Cash position
- 430629000
- Credit facility draw
- 20000000
- Credit facility total
- 200000000
- Treatment burden reduction overall
- 78%
- Treatment burden reduction recent dx
- 87%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.